MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.

As prognostic factors, MYC and MYCN amplifications are routinely assessed in medulloblastomas. Fluorescence in situ hybridization (FISH) is currently considered as the technique of reference. Recently, array comparative genomic hybridization (aCGH) has been developed as an alternative technique to evaluate genomic abnormalities in other tumor types; however, this technique has not been widely adopted as a replacement for FISH in medulloblastoma. In this study, 34 tumors were screened by both FISH and aCGH. In all cases showing amplification by FISH, aCGH also unambiguously revealed the abnormality. The aCGH technique was also performed on tumors showing no amplification by FISH, and the absence of amplification was confirmed in all cases. Interestingly, one tumor showed a subclonal MYC amplification by FISH. This subclonal amplification was observed in approximately 20% of tumor cells and was clearly evident on aCGH. In conclusion, our analysis confirms that aCGH is as safe as FISH for the detection of MYC/MYCN gene amplification. Given its cost efficiency in comparison to two FISH tests and the global genomic information additionally provided by an aCGH experiment, this reproducible technique can be safely retained as an alternative to FISH for routine investigation of medulloblastoma. Copyright © 2013 Elsevier Inc. All rights reserved.

Citation

Franck Bourdeaut, Camille Grison, Claude-Alain Maurage, Annie Laquerriere, Alexandre Vasiljevic, Marie-Bernadette Delisle, Sophie Michalak, Dominique Figarella-Branger, François Doz, Wilfrid Richer, Gaelle Pierron, Catherine Miquel, Olivier Delattre, Jérôme Couturier. MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. Cancer genetics. 2013 Apr;206(4):124-9

Mesh Tags

Substances

PMID: 23578955

search → result